|Registration Date||19 Jul 2017|
Medicine Medical SuppliesProstate Cancer Blood Test
The only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer Armune BioScience, in partnership with the University of Michigan, has developed a new technology that measures specific biological markers known to be associated with an immune system response to cancer.Apifiny® is a simple blood test that measures specific biological markers known to be associated with an immune system response to prostate cancer. Such autoantibodies are detectable in patient’s serum, providing the basis for this diagnostic blood test.Now available for commercial use, Apifiny® is our proprietary, patented technology that may aid clinicians in the assessment of risk for the presence of prostate cancer.Apifiny® measures eight autoantibodies released by the immune system in response to the presence of prostate cancer.Apifiny® autoantibodies were discovered by research conducted at the University of Michigan under the direction of Arul Chinnaiyan, MD, PhD.Apifiny® does not rely on PSA or a calculation based on various forms of PSA.Orders for the Apifiny® must be made by a physician (or authorized representative) using the Apifiny® Test Requisition Form.The Apifiny® test requires 5 mL of blood or 1 mL of serum.
It is well known that early detection improves long-term survival rates, therefore this technology along with current screening and detection methods, including family history, may provide additional insight for clinicians to aid in a clinical decision for determining a patient’s risk of prostate cancer. By all accounts, the current methods for the screening and detection of prostate cancer using PSA testing, family history, digital rectal exam, and prostate biopsies are not perfect.